Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response.

Nature communications·2026
Same author

Prognostic value of postoperative day 1 prolactin following prolactinoma resection.

Journal of neurosurgery·2026
Same author

IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma.

Cancer research·2026
Same author

Resection versus fenestration for Rathke's cleft cysts: a propensity score-matched analysis of long-term outcomes.

Journal of neurosurgery·2026
Same author

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Molecular biology of pituitary neuroendocrine tumors.

Journal of neuro-oncology·2026
Same journal

A novel surgical T staging system for recurrent nasopharyngeal carcinoma: advancing prognostic accuracy and clinical applicability.

Journal of neurosurgery·2026
Same journal

De novo aneurysm formation and untreated aneurysm growth after microsurgical clipping: a 20-year prospective cohort study.

Journal of neurosurgery·2026
Same journal

Immune and clinicopathological features of molecularly defined prolactinoma subtypes.

Journal of neurosurgery·2026
Same journal

A nomogram predicting postoperative recurrence risk in SF1/TPIT nonfunctioning pituitary neuroendocrine tumors: integration of tumor heterogeneity quantification on T2-weighted imaging.

Journal of neurosurgery·2026
Same journal

Resection plus stereotactic radiosurgery versus stereotactic radiosurgery alone and control of brain metastasis-induced seizures.

Journal of neurosurgery·2026
Same journal

Predictors of ventricular shunt survival in neoplastic hydrocephalus: a retrospective cohort study of 239 patients.

Journal of neurosurgery·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Dopamine agonist-resistant prolactinomas.

Michael C Oh1, Manish K Aghi

  • 1California Center for Pituitary Disorders, Department of Neurological Surgery, University of California, San Francisco, California 94143-0112, USA.

Journal of Neurosurgery
|January 11, 2011
PubMed
Summary
This summary is machine-generated.

Dopamine agonist-resistant prolactinomas (DARPs) are rare but aggressive brain tumors. Current treatments are challenging, highlighting the need for new therapies to manage these resistant tumors.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: Jun 5, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

  • Neuro-oncology
  • Endocrinology
  • Tumor Biology

Background:

  • Prolactinomas are brain tumors typically responsive to dopamine agonists.
  • A small percentage of prolactinomas are resistant to dopamine agonist therapy, termed dopamine agonist-resistant prolactinomas (DARPs).

Purpose of the Study:

  • To review the definition, epidemiology, biology, resistance mechanisms, and treatment of DARPs.
  • To highlight the aggressive nature and management challenges of DARPs.

Main Methods:

  • Literature review of studies on dopamine agonist-resistant prolactinomas.
  • Analysis of tumor characteristics, resistance mechanisms, and treatment outcomes.

Main Results:

  • DARPs are more common in males and present as invasive macroadenomas.
  • These tumors exhibit increased angiogenesis, proliferation, and cellular atypia.
  • Estrogen receptor antagonists and temozolomide are common alternative therapies.

Conclusions:

  • DARPs display aggressive behavior, posing management challenges.
  • Novel therapeutic strategies are needed for effective treatment of these resistant tumors.